Fibronectin staining indicated that CLC‐PTX treatment blocked the formation of excessive ECM in both the primary 4T1 tumor and TDLN significantly, suggesting that CLC‐based drug conjugates render the ECM environment less favorable for cancer growth through their concentration of the chemotherapeutic drug at the cancer site. This evidence concerns the gene FN1 and neoplasm.